AU2003211362A1 - N-hydroxycarboxamide derivative - Google Patents

N-hydroxycarboxamide derivative

Info

Publication number
AU2003211362A1
AU2003211362A1 AU2003211362A AU2003211362A AU2003211362A1 AU 2003211362 A1 AU2003211362 A1 AU 2003211362A1 AU 2003211362 A AU2003211362 A AU 2003211362A AU 2003211362 A AU2003211362 A AU 2003211362A AU 2003211362 A1 AU2003211362 A1 AU 2003211362A1
Authority
AU
Australia
Prior art keywords
hydroxycarboxamide
derivative
hydroxycarboxamide derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003211362A
Inventor
Yasuo Nagaoka
Shinichi Uesato
Takao Yamori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka Industrial Promotion Organization
Original Assignee
Osaka Industrial Promotion Organization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka Industrial Promotion Organization filed Critical Osaka Industrial Promotion Organization
Publication of AU2003211362A1 publication Critical patent/AU2003211362A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes
AU2003211362A 2002-02-21 2003-02-18 N-hydroxycarboxamide derivative Abandoned AU2003211362A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002045310 2002-02-21
JP2002-45310 2002-02-21
JP2002-235912 2002-08-13
JP2002235912 2002-08-13
PCT/JP2003/001681 WO2003070691A1 (en) 2002-02-21 2003-02-18 N-hydroxycarboxamide derivative

Publications (1)

Publication Number Publication Date
AU2003211362A1 true AU2003211362A1 (en) 2003-09-09

Family

ID=27759672

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003211362A Abandoned AU2003211362A1 (en) 2002-02-21 2003-02-18 N-hydroxycarboxamide derivative

Country Status (3)

Country Link
JP (1) JPWO2003070691A1 (en)
AU (1) AU2003211362A1 (en)
WO (1) WO2003070691A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2403474B (en) * 2002-04-18 2006-10-11 Inst Med Molecular Design Inc Amide derivatives
ITMI20030064A1 (en) 2003-01-17 2004-07-18 Italfarmaco Spa USE OF HYDROXAMIC ACID DERIVATIVES FOR PREPARATION
EP1608319A4 (en) 2003-04-03 2007-02-28 Univ California Improved inhibitors for the soluble epoxide hydrolase
SI1611088T1 (en) 2003-04-07 2009-12-31 Pharmacyclics Inc Hydroxamates as therapeutic agents
DE602004004665T2 (en) 2003-08-20 2008-01-03 Pharmacyclics, Inc., Sunnyvale Acetyl derivatives as inhibitors of histone deacetylase
ES2562778T3 (en) 2003-12-02 2016-03-08 The Ohio State University Research Foundation Short chain fatty acids linked to chelating Zn2 + motifs as a novel class of histone deacetylase inhibitors
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
ITMI20041347A1 (en) * 2004-07-05 2004-10-05 Italfarmaco Spa ALPHA-AMINO ACID DERIVATIVES FOR ANTI-INFLAMMATORY ACTIVITIES
AU2005295167B2 (en) * 2004-10-20 2012-05-10 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
WO2007095561A2 (en) * 2006-02-15 2007-08-23 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
CN101460458A (en) 2006-02-15 2009-06-17 阿勒根公司 Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
WO2008074132A1 (en) * 2006-12-19 2008-06-26 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
DK2099442T3 (en) 2006-12-26 2015-02-16 Pharmacyclics Inc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
KR20090101307A (en) * 2007-01-11 2009-09-24 알러간, 인코포레이티드 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
EP2993473A1 (en) 2007-01-30 2016-03-09 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
WO2008126731A1 (en) * 2007-04-05 2008-10-23 Daiichi Sankyo Company, Limited Aryl derivatives
WO2009079375A1 (en) * 2007-12-14 2009-06-25 Georgetown University Histone deacetylase inhibitors
WO2010043953A2 (en) * 2008-10-15 2010-04-22 Orchid Research Laboratories Ltd. Novel bridged cyclic compounds as histone deacetylase inhibitors
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US20110212969A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8546588B2 (en) 2010-02-26 2013-10-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CN102775368B (en) * 2011-05-10 2016-08-17 上海驺虞医药科技有限公司 One class thiazole compound and its production and use
CN103917231B (en) 2011-09-13 2016-09-28 药品循环有限责任公司 Combination formulations of histone deacetylase inhibitor and bendamustine and application thereof
CA2866707A1 (en) * 2012-03-07 2013-09-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Selective histone deactylase 6 inhibitors
US9409858B2 (en) 2012-03-07 2016-08-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Selective histone deactylase 6 inhibitors
RU2634694C2 (en) * 2013-04-29 2017-11-03 Чонг Кун Данг Фармасьютикал Корп. New compounds for selective histone deacetylase inhibitors and pharmaceutical composition including such compounds
WO2015017546A1 (en) 2013-07-30 2015-02-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Selective histone deactylase 6 inhibitors
TWI649081B (en) 2013-08-02 2019-02-01 製藥公司 Method for treating solid tumors
WO2015058106A1 (en) * 2013-10-18 2015-04-23 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
TWI659949B (en) 2016-05-16 2019-05-21 臺北醫學大學 Histone deacetylase 6 inhibitors and use thereof
CN107141244B (en) * 2017-05-08 2019-11-19 潍坊医学院 Indolebutyric acid class inhibitors of histone deacetylase and its preparation method and application
CN113444038B (en) * 2021-07-07 2022-09-27 新乡医学院 2-aryl isonicotinic acid amide LSD1/HDAC double-target inhibitor, and preparation method and application thereof
CN113527195B (en) * 2021-07-07 2022-09-20 新乡医学院 5-aryl nicotinamide LSD1/HDAC double-target inhibitor, preparation method and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04217950A (en) * 1990-03-28 1992-08-07 Asahi Chem Ind Co Ltd Hydroxamic acid derivative, enzyme inhibitor and antiulcer agent
JPH11514857A (en) * 1995-09-20 1999-12-21 メルク エンド カンパニー インコーポレーテッド Histone deacetylase as a target for antiprotozoal agents
IT1283637B1 (en) * 1996-05-14 1998-04-23 Italfarmaco Spa COMPOUNDS WITH ANTI-INFLAMMATORY AND IMMUNOSOPPRESSIVE ACTIVITY
JPH11335375A (en) * 1998-05-20 1999-12-07 Mitsui Chem Inc Benzamide derivative having histone deacetylase inhibiting action
JP4269041B2 (en) * 1999-03-02 2009-05-27 国立大学法人九州工業大学 Novel cyclic tetrapeptide derivatives and their pharmaceutical uses
JP2001081031A (en) * 1999-08-30 2001-03-27 Schering Ag Benzamide derivative-containing preparation having improved solubility and oral adsorption
AU783504C (en) * 1999-11-23 2006-08-03 Methylgene Inc. Inhibitors of histone deacetylase
WO2002074298A1 (en) * 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Il-6 production inhibitors
ITMI20011733A1 (en) * 2001-08-07 2003-02-07 Italfarmaco Spa HYDROXAMIC ACID DERIVATIVES HISTONE DEHYACETYLASE ENZYM INHIBITORS, WHICH NEW ANTI-INFLAMMATORY DRUGS INHIBIT CITOC SYNTHESIS

Also Published As

Publication number Publication date
WO2003070691A1 (en) 2003-08-28
JPWO2003070691A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
AU2003211362A1 (en) N-hydroxycarboxamide derivative
AU2003239909A1 (en) Enhanced-service provision
AU2003224111A1 (en) Substituted pyrazolo-pyrimidine-4-ones
AU2002335152A1 (en) Robot-phone
WO2003072535A8 (en) Substituted hydroxyethylamines
AU2003238043A1 (en) Substituted imidazotriazines
AU2003245984A1 (en) Hetero-cyclicaly substituted imidazotriazines
AU2003301968A1 (en) 4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2003294900A1 (en) Substituted 5-aminomethyl-1h-pyrrole-2-carboxamides
AU2003278369A1 (en) 3-cyano-quinoline derivatives
AU2003296564A1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
AU2003222659A1 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003234131A1 (en) 5-o-mycaminosyltylonide derivatives
AU2003212366A1 (en) Substituted 4-aminocyclohexanols
AU2002367810A1 (en) Bis-transition-metal-chelate-probes
AU2002249639A1 (en) Pyranocoumarin derivatives
AU2003273398A1 (en) Aroyl-piperidine derivatives
AU2003238180A1 (en) 2-naphtamide derivatives
AU2003288012A1 (en) Isothiazolyl-benzoxazine derivatives
AU2002368348A1 (en) Electrosomatogram
AU2002318053A1 (en) Suplier
AU2003243397A1 (en) Homo-camptothecin derivatives
AU2003284704A1 (en) Substituted 1h-pyridine-2-one derivatives
AU2002348964A1 (en) Snowbike
AU2002341221A1 (en) Honey-brandy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase